Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to equity ratio is N/A as of Tuesday, October 6, 2026.
DEBT TO EQUITY RATIO
N/A
Market Cap
$1.52B
Debt to Equity Ratio
0.62
TTM Avg
1.21
3Y Avg
0.82
5Y Avg
0.68
Market Cap
$1.45B
Debt to Equity Ratio
0.03
TTM Avg
0.04
3Y Avg
0.07
5Y Avg
0.06
Market Cap
$1.43B
Debt to Equity Ratio
0.00
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.39B
Debt to Equity Ratio
N/A
TTM Avg
6.73
3Y Avg
5.46
5Y Avg
3.96
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | $1.51B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.52B | 0.00 | 0.00 | 0.00 | 0.00 |
| Innoviva, Inc. (INVA)vs › | $1.52B | 0.22 | 0.44 | 0.63 | 0.69 |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.52B | 0.62 | 1.21 | 0.82 | 0.68 |
| AnaptysBio, Inc. (ANAB)vs › | $1.46B | 25.47 | 2.79 | 1.47 | 0.99 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 0.03 | 0.04 | 0.07 | 0.06 |
| Certara, Inc. (CERT)vs › | $1.57B | 0.30 | 0.15 | 0.22 | 0.26 |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.43B | 0.00 | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | N/A | 6.73 | 5.46 | 3.96 |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | N/A | 40.93 | 29.06 | 18.39 |
Debt/Equity
N/A
Current Ratio
N/A
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
